Interestingly, BCG treatment upregulated PD-L1 expression in tumor tissue, and combined BCG plus anti-PD-L1 therapy demonstrated tumor weight reduction and boosted circulating CD8+ immune responses as compared to BCG alone. Here, CD8A is linked to neoplasm.